Notably, advanced BRAF p.V600E-mutated carcinomas, including anaplastic and iodide-refractory non-anaplastic carcinomas, can be treated with molecularly targeted therapies, such as dabrafenib (BRAF inhibitor) and trametinib (MAPK inhibitor). Here, BRAF is linked to carcinoma.